| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |